Needham & Company Boosts PT on Gilead Sciences (GILD) to $62

May 3, 2013 9:14 AM

Needham & Company raised its price target on Buy-rated Gilead Sciences (NASDAQ: GILD) from $45 to $62 on impressive Sofosbuvir/Ledipasvir ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found